Cellectar Biosciences announced that an abstract describing data from its CLOVER‑WaM study has been accepted for a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 1, 2026. The study focuses on iopofosine I‑131, a phospholipid drug conjugate that delivers targeted iodine‑131 radioisotope therapy to patients with relapsed or refractory Waldenström Macroglobulinemia (WM) who have progressed after BTK inhibitor therapy.
Waldenström Macroglobulinemia is a rare B‑cell malignancy affecting roughly 26,000 people in the United States, with 1,500–1,900 new cases each year. Approximately 11,500 patients require treatment in the relapsed or refractory setting, and about 4,700 need third‑line or greater therapy. Current options after BTK inhibitor failure are limited, and more than 60% of treatments are salvage therapies with modest benefit. Iopofosine I‑131 has received multiple U.S. FDA designations—including Breakthrough Therapy, Orphan Drug, Rare Pediatric Drug, and Fast Track—as well as the European Medicines Agency’s PRIME designation, underscoring regulatory interest in this novel approach.
In its most recent quarterly report, Cellectar reported a fourth‑quarter 2025 earnings per share of –$0.53, a beat of $0.68 (56.20%) over the consensus estimate of –$1.21. The company’s net loss for FY2025 was $21.8 million, an improvement from $44.6 million in FY2024, and it ended the year with $13.2 million in cash, providing a runway to fund operations into 2026. The company’s market capitalization was approximately $12.3 million as of April 20, 2026.
COO Jarrod Longcor highlighted the unmet need for patients who progress after BTK inhibitors, noting that over 60% of current treatments are salvage therapies with limited benefit. CEO James Caruso emphasized that the FDA’s Breakthrough Therapy designation “underscores the potential of iopofosine I‑131 as it may offer substantial improvement on at least one clinically significant endpoint over available therapies to address the substantial unmet medical need in this life‑threatening cancer.”
The acceptance of the abstract at ASCO provides Cellectar with a high‑profile venue to present its data to a global audience of oncologists, researchers, and potential partners. The presentation is a key step in advancing the drug’s regulatory and commercialization path and may attract additional investment or collaboration opportunities. In the competitive landscape, existing BTK inhibitors dominate first‑line therapy, but options after progression are scarce, positioning iopofosine I‑131 as a potentially differentiated treatment.
Overall, the abstract acceptance marks a pivotal milestone for Cellectar’s iopofosine I‑131 program, reinforcing the company’s progress toward regulatory approval and strengthening its position in the niche but growing market for relapsed or refractory Waldenström Macroglobulinemia.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.